In short
FWY003 tosilate is an investigational oral capsule being studied for geographic atrophy secondary to age-related macular degeneration (AMD). It is a chemically synthesised substance developed by Novartis Pharma AG, with no marketing authorisation in the product records. One Phase 2 trial is authorised, planning to enrol 272 participants to measure change in geographic atrophy lesion area over 18 months.
Key points
- FWY003 tosilate is an investigational oral capsule, not yet authorised as a medicine.
- It is being studied in geographic atrophy secondary to age-related macular degeneration, an advanced form of dry AMD.
- The single authorised trial is a Phase 2, dose-range finding study with 272 planned participants.
- The trial is placebo-controlled and double-masked, meaning neither participants nor researchers know who receives FWY003 or placebo.
- The main outcome is change in geographic atrophy lesion area from baseline to month 18.
- FWY003 is given orally as a capsule.
What is FWY003 tosilate?
FWY003 tosilate, also referred to as FWY003, is a chemically synthesised substance being developed by Novartis Pharma AG. It is an investigational medicine, meaning it has no marketing authorisation in the product records and is not yet approved for routine clinical use. The substance is classified under the therapeutic area of eye diseases. FWY003 is being studied as a potential treatment for geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD) that leads to progressive loss of central vision.
How does FWY003 tosilate work?
The available registry records do not describe a specific molecular target or mechanism of action for FWY003 tosilate. The trial is designed to evaluate a dose-response relationship, meaning it will assess whether different doses of FWY003 have different effects on the geographic atrophy lesion area. The primary endpoint measures change in GA lesion area from baseline to month 18, which reflects whether the treatment can slow the enlargement of areas of retinal cell loss.
Which conditions is FWY003 tosilate studied for?
- Geographic atrophy secondary to age-related macular degeneration — an advanced form of dry AMD in which regions of the retina lose cells, causing progressive and irreversible vision loss. FWY003 is being tested to see whether it can reduce the growth of these atrophic lesions.
How is FWY003 tosilate given?
FWY003 tosilate is formulated as a capsule and is given by oral administration, meaning it is taken by mouth. The trial uses the capsule form, with the dose-ranging design intended to identify which dose may be most effective and tolerable.
What do the clinical trials show?
One clinical trial of FWY003 tosilate is registered in the EU Clinical Trials Information System. It is a Phase 2, randomised, double-masked, placebo-controlled, multicentre, dose-range finding study in participants with geographic atrophy secondary to AMD. The trial is authorised and is planned to enrol 272 participants. The primary outcome is the change in GA lesion area from baseline to month 18, used to assess the dose-response relationship of FWY003. The trial includes placebo as a comparison arm, and participants are assigned to different FWY003 dose groups or placebo.
What side effects are known?
The registry record and the supplementary source do not report specific side effects for FWY003 tosilate. The trial is designed to assess both efficacy and safety, but no adverse event data are available in the provided sources.